The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer

Author： Suzuki Takeshi   Mitsudomi Tetsuya   Hida Toyoaki  

Publisher： Future Medicine

ISSN： 1741-0541

Source： Personalized Medicine, Vol.1, Iss.1, 2004-12, pp. : 27-34

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations

By  

Oncology, Vol. 89, Iss. 5, 2015-0 ,pp. : 275-280

Karger

Access to resources Recommend Favorite

Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations

By  

Oncology Research and Treatment, Vol. 40, Iss. 1-2, 2017-01 ,pp. : 7-13

Karger

Access to resources Recommend Favorite

EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non–small cell lung carcinoma patients

By  

CANCER CYTOPATHOLOGY, Vol. 121, Iss. 10, 2013-10 ,pp. : 552-560

John Wiley & Sons Inc

Access to resources Recommend Favorite

The prevalence of EGFR mutations in non‐small cell lung cancer in an unselected Caucasian population

By  

APMIS (ELECTRONIC), Vol. 123, Iss. 2, 2015-02 ,pp. : 108-115

John Wiley & Sons Inc

Access to resources Recommend Favorite

EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Report of a 3-Year Compassionate Use Experience with Gefitinib in Stage IIIB/IV Outpatients

By  

Oncology Research and Treatment, Vol. 28, Iss. 12, 2005-12 ,pp. : 623-627

Karger

Access to resources Recommend Favorite